More Backing for HOLX Tomosynthesis - Analyst Blog
17 Aprile 2013 - 5:02PM
Zacks
Leading player in the women’s
health market Hologic Inc. (HOLX) continues to
leap forward with positive data supporting the adoption of its
tomosynthesis technology. The company stated that the latest online
publication of a new study by European Radiology supports
the efficacy of the company’s tomosynthesis technology over the
2-dimensional (2D) imaging in breast cancer screening programs.
The European Radiology paper is the first peer-reviewed
publication to examine the performance of double reading of 2D
mammography in contrast to double reading of 2D mammography plus
tomosynthesis imaging in a large prospective clinical study. The
study – ‘Prospective Trial Comparing Full-field Digital Mammography
(FFDM) versus Combined FFDM and Tomosynthesis in a Population-based
Screening Programme Using Independent Double Reading with
Arbitration’ shows the technical advancement of Hologic’s breast
tomosynthesis technology.
The study encompassed 12,621 screening examinations of women
participating in the Oslo Tomosynthesis Screening Trial. The
researchers concluded that double-reading of tomosynthesis based
examinations decreased false-positive interpretations by 18%. Also,
double-reading of tomosynthesis based examinations improved breast
cancer detection by 30%.
The Oslo data further supports the use of Hologic’s tomosynthesis
technology to improve detection rate. Management is optimistic that
the proven strong clinical benefits of its tomosynthesis technology
should improve adoption rates.
Earlier, in Jan 2013, the company disclosed results from the
crucial Oslo clinical study which advocates the use of Hologic’s 3D
breast tomosynthesis screening technology in addition to the 2D
breast screening exam. Management states this to be a landmark
revelation as the Oslo trial is the first large-scale prospective
study to support its 3D tomosynthesis technology platform.
Our View
We believe that publication of peer-reviewed study should ramp up
adoption rates and support Hologic’s efforts to gain reimbursement
for its tomosynthesis technology. Notably, company expectations
from the tomosynthesis technology are very high. Hologic’s
consistent efforts to promote the technology are likely to yield
positive results.
Currently, the stock carries a Zacks Rank #3 (Hold). While we
remain on the sidelines for Hologic, other healthcare stocks such
as Cyberonics Inc. (CYBX) and
Cepheid (CPHD), carrying a Zacks Rank #1 (Strong
Buy) warrant a look. Mindray Medical International
Limited (MR), carrying a Zacks Rank #2 (Buy) is also worth
considering.
CEPHEID INC (CPHD): Free Stock Analysis Report
CYBERONICS INC (CYBX): Free Stock Analysis Report
HOLOGIC INC (HOLX): Free Stock Analysis Report
MINDRAY MEDICAL (MR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Grafico Azioni Montage Resources (NYSE:MR)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Montage Resources (NYSE:MR)
Storico
Da Lug 2023 a Lug 2024
Notizie in Tempo Reale relative a Montage Resources Corporation (Borsa di New York (NYSE)): 0 articoli recenti
Più Mindray Medical International Limited Sponsored Adr Representing Class A Shares (China) Articoli Notizie